<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="NS4b, NS5a, and NS5B) (reviewed in reference [1]). Human HCV" exact="infection" post="causes chronic liver disease, cirrhosis, and is associated with"/>
 <result pre="with HCV [3] and given the chronic nature of the" exact="infection" post="it is expected that the number of patients with"/>
 <result pre="increase in the coming years. The standard therapy for the" exact="treatment" post="of chronically HCV infected patients consists of a combination"/>
 <result pre="associated with injections of interferon, an interferon-free regimen for the" exact="treatment" post="of HCV infections is highly desirable. Recent studies have"/>
 <result pre="the inclusion of ribavirin in interferon free regimens in the" exact="treatment" post="of chronic HCV, cross resistance of HCV to ribavirin"/>
 <result pre="(5 mM) and 5-Fluorouracil (200 or 500 µg/ml) for the" exact="treatment" post="of BHK-21 cells used by Perales and colleagues are"/>
 <result pre="drug selection, since an interferon-free regimen containing ribavirin for the" exact="treatment" post="of HCV infections seems currently plausible. We isolated a"/>
 <result pre="the day before, and at 5 to 7 hours post" exact="infection" post="medium was replaced with 500 µl of medium containing"/>
 <result pre="FlammSL, AfdhalNH, NelsonDR, SulkowskiMS, et al. (2011) Response-guided telaprevir combination" exact="treatment" post="for hepatitis C virus infection. N Engl J Med365:"/>
 <result pre="rate of the hepatitis C virus NS5B in patients undergoing" exact="treatment" post="with ribavirin monotherapy. Gastroenterology132: 1757–1766.17484873 28DietzJ, SchelhornSE, FittingD, MihmU,"/>
 <result pre="et al... (2004) First clinical results for a novel antiviral" exact="treatment" post="for hepatitis C: a phase I/III dose escalation trial"/>
 <result pre="tolerance, pharmacokinetics and antiviral activity on NM283, a novel antiviral" exact="treatment" post="for hepaititis C. Gastroenterology. 33AfdahlN, GodofskyE, DienstagJ, RustgiV, SchickL,"/>
 <result pre="multiple, ascending, oral doses in patients with HCV Genotype 1" exact="infection" post="who have failed prior interferon therapy. 58th Annual Meeting"/>
</results>
